Figure 2From: Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer’s disease: a phase I studyPlots illustrating cerebrospinal fluid β-amyloid Ab(1–42) levels for individuals by time and dose level for each dose group. GSK: GSK933776. Patients = 6 per group.Back to article page